
In patients with low-risk differentiated thyroid cancer undergoing thyroidectomy, the postoperative administration of radioiodine (iodine-131) is controversial without demonstrated benefits. In patients with low-risk thyroid cancer undergoing thyroidectomy, a follow-up strategy that did not involve radioiodine was non-inferior to an ablation strategy with radioiodine regarding the occurrence of functional, structural, and biologic events at three years.
Like
Save
Share